8:30 am Join Our Morning Coffee Chatroom to Get Started!

8:45 am Chair’s Opening Remarks

• Ganesh Mugundu Head of Cell Therapy Clinical Pharmacology & Modelling, Takeda

Model Innovation for Cell Therapies

9:00 am Use of Humanized Mouse Models for Better Translation in Immunotherapy

• Qingcong Lin Chief Executive Officer, Biocytogen

9:30 am Blending Tumor Models and Engineering to Accelerate Natural Killer Cell Therapies in Glioblastoma Multiformel

• Aaron Goldman Director, Drug Resistance Group, Harvard Medical School

9:50 am Orthotopic PDX Models Provide Relevant Tumor Microenvironments For Evaluating Cellular Therapies

• Jonathan Nakashima Chief Scientific Officer, Certis Oncology Solutions

10:05 am Live Q&A

• Ganesh Mugundu Head of Cell Therapy Clinical Pharmacology & Modelling, Takeda
• Qingcong Lin Chief Executive Officer, Biocytogen
• Aaron Goldman Director, Drug Resistance Group, Harvard Medical School
• Jonathan Nakashima Chief Scientific Officer, Certis Oncology Solutions

10:30 am Speed Networking

10:50 am Morning Networking Break & 1-2-1 Meetings

Novel Insights into Tumor Mechanisms & the Immune System

11:00 am NCG Models for Engraftment of Human Immune Systems

• Mark Moore Chief Executive Officer, GemPharmatech

11:15 am Conditionally Active COBRA T Cell Engagers Regress stablished Solid Tumors in Mice

• Chad May Senior Vice President, Research & Development, Maverick Therapeutics

11:35 am Understanding the Mechanistic Actions & Development of IL-15Rβγ Agonist

• Irena Adkins Pharmacology & Science Lead, SOTIO

11:55 am Novel Preclinical Models for Investigation of Immune Oncology Therapeutics

• Viswanathan Muthusamy Research Scientist, Executive Director, Yale School of Medicine

12:15 pm Live Q&A – Ask Our Speakers Your Burning Questions

• Ganesh Mugundu Head of Cell Therapy Clinical Pharmacology & Modelling, Takeda
• Chad May Senior Vice President, Research & Development, Maverick Therapeutics
• Irena Adkins Pharmacology & Science Lead, SOTIO
• Viswanathan Muthusamy Research Scientist, Executive Director, Yale School of Medicine
• Mark Moore Chief Executive Officer, GemPharmatech

12:30 pm Scientific Poster Session & Lunch Break

1:20 pm Panel: Diversity & Inclusion in Preclinical & Translational Studies

• Shiva Kazerounian Associate Director of in Vivo Pharmacology, Berg Health
• Irena Adkins Pharmacology & Science Lead, SOTIO
• Ganesh Mugundu Head of Cell Therapy Clinical Pharmacology & Modelling, Takeda

Guiding Clinical Design

2:00 pm Bench to Bedside Translation of Chimeric Antigen Receptor (CAR) T Cells Using a Multiscale Systems PKPD Model

• Aman Singh Associate Director, Clinical Pharmacology M&S, Takeda

2:20 pm Translating Pre-Clinical Data into Innovative Clinical Trial Designs in Cell Therapies

• Markus Vallaster Senior Medical Director, Cell Therapies & Immuno-Oncology, AstraZeneca

2:40 pm Clinical Pharmacology of Tisagenlecleucel in Adult Relapsed/ Refractory DLBCL Patients

• Rakesh Awasthi Clinical Pharmacology, Pharmacokinetic Oncology Sciences & Investigator, Novartis

3:00 pm Clinical Dosing – Clinical Pharmacology & Modelling of Cell Therapies

• Ganesh Mugundu Head of Cell Therapy Clinical Pharmacology & Modelling, Takeda

3:20 pm Live Q&A – Ask Our Speakers Your Burning Questions

• Ganesh Mugundu Head of Cell Therapy Clinical Pharmacology & Modelling, Takeda
• Markus Vallaster Senior Medical Director, Cell Therapies & Immuno-Oncology, AstraZeneca
• Aman Singh Associate Director, Clinical Pharmacology M&S, Takeda
• Rakesh Awasthi Clinical Pharmacology, Pharmacokinetic Oncology Sciences & Investigator, Novartis

3:40 pm Chair’s Closing Remarks & End of Summit

• Ganesh Mugundu Head of Cell Therapy Clinical Pharmacology & Modelling, Takeda